Bradford Bergman, MD
Internal Medicine · Great Falls, MTNPI 1235130113
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $713 and has fallen 70.0% since, to $214 in 2025. Among internal medicine clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$276
- Amgen$264
- Corcept Therapeutics$225
- AstraZeneca$209
- Merck$172
- E.r. Squibb & Sons, L.L.C.$171
- plus $871 from 18 others
What the payments were for
- Food & beverage$2,187100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $276 |
| Amgen | 15 | $264 |
| Corcept Therapeutics | 7 | $225 |
| AstraZeneca | 12 | $209 |
| Merck | 12 | $172 |
| E.r. Squibb & Sons, L.L.C. | 10 | $171 |
| Novartis | 8 | $112 |
| Pfizer | 8 | $107 |
| Novo Nordisk | 6 | $100 |
| Exact Sciences | 5 | $72 |
| AbbVie(2 entities) | 3 | $68 |
| Astellas Pharma US Inc | 3 | $65 |
| Johnson & Johnson(2 entities) | 4 | $52 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Boehringer Ingelheim | 2 | $39 |
| Lundbeck LLC | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $26 |
| Lilly USA, LLC | 2 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Averitas Pharma Inc. | 1 | $20 |
| Verona Pharma, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
How this compares
$2,187 in reported general payments places this provider in the 95th percentile of 244 internal medicine providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 222 | $228,108 |
| OzempicSemaglutide | 160 | $213,631 |
| JardianceEmpagliflozin | 83 | $95,757 |
| FarxigaDapagliflozin Propanediol | 89 | $81,795 |
| XareltoRivaroxaban | 90 | $72,170 |
| TrulicityDulaglutide | 34 | $45,820 |
| MounjaroTirzepatide | 25 | $24,916 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $23,018 |
| MyrbetriqMirabegron | 31 | $21,335 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $17,881 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $12,949 |
| LivaloPitavastatin Calcium | 14 | $11,390 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $11,257 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $10,930 |
| PremarinEstrogens, Conjugated | 11 | $9,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $107 | $237,597233 claims |
| Novo NordiskOzempic | $100 | $213,631160 claims |
| Boehringer IngelheimJardiance | $39 | $95,75783 claims |
| AstraZenecaFarxiga | $209 | $81,79589 claims |
| Johnson & JohnsonXarelto | $52 | $72,17090 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $23 | $70,73659 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $276 | $53,84970 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $21,33531 claims |
| AbbVieCreon | $68 | $8,31913 claims |
| Daiichi Sankyo Inc.Savaysa | $33 | $5,27413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 244 internal medicine providers in Montana.
Other internal medicine in Great Falls
- Stacy KingslandGreat Falls$5K
- Nicholas TrumGreat Falls$2K
- Steven ChrzanowskiGreat Falls$2K
- Scott BurkGreat Falls$1K
- Kathleen BlairGreat Falls$1K
- Katherine ZitelloGreat Falls$682
- Eve GerasimouGreat Falls$661
- Berilonson OsiroGreat Falls$340
- James LeganGreat Falls$312
- Hanna BroniewskaGreat Falls$193
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.